Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Chiasma Inc (CHMA) USD0.01

Sell:$5.20 Buy:$5.22 Change: $0.02 (0.38%)
NASDAQ:0.22%
Market closed |  Prices as at close on 13 September 2019 | Switch to live prices |
Sell:$5.20
Buy:$5.22
Change: $0.02 (0.38%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 13 September 2019 | Switch to live prices |
Sell:$5.20
Buy:$5.22
Change: $0.02 (0.38%)
Market closed |  Prices as at close on 13 September 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Contact details

Address:
460 Totten Pond Rd Ste 530
WALTHAM
02451-1944
United States
Telephone:
+1 (617) 9285300
Website:
www.chiasmapharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CHMA
ISIN:
US16706W1027
Market cap:
$219.38 million
Shares in issue:
41.79 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Stack
    Independent Chairman of the Board
  • Mark Fitzpatrick
    President, Principal Financial Officer
  • Raj Kannan
    Chief Executive Officer, Director
  • William Ludlam
    Senior Vice President - Clinical Development and Medical Affairs
  • Drew Enamait
    Principal Accounting Officer, Vice President - Finance & Administration, Corporate Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.